5-HT-related drugs and human experimental anxiety (Q38033023)

27 August 2017

1 reference

title

5-HT-related drugs and human experimental anxiety (English)

1 reference

27 August 2017

Zuardi AW

1

1 reference

27 August 2017

publication date

1 January 1990

1 reference

Neuroscience & Biobehavioral Reviews

27 August 2017

published in

1 reference

27 August 2017

volume

14

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

507-510

1 reference

Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

5HT2 receptors, depression and anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Antiobsessive effect of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Effect of metergoline on human anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Effect of chlorimipramine and maprotiline on experimental anxiety in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Serotonin and anxiety revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Zimeldine treatment of obsessive-compulsive disorder. Biological and neuropsychological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Clomipramine and exposure for obsessive-compulsive rituals: i

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Pharmacological and clinical effects of buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

1 reference

7 January 2021

Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2805%2980075-2

7 January 2021

10.1016/S0149-7634(05)80075-2

Identifiers

DOI

1 reference

27 August 2017

1 reference